Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 522.83 million compared to CNY 271.26 million a year ago. Net income was CNY 68.44 million compared to net loss of CNY 35.97 million a year ago.

Basic earnings per share from continuing operations was CNY 0.07 compared to basic loss per share from continuing operations of CNY 0.03 a year ago. Diluted earnings per share from continuing operations was CNY 0.07 compared to diluted loss per share from continuing operations of CNY 0.03 a year ago.